A randomized, double-blind, placebo-controlled factorial study evaluating the efficacy and safety of co-administration of olmesartan medoxomil plus amlodipine compared to monotherapy in patients with mild to severe hypertension

Trial Profile

A randomized, double-blind, placebo-controlled factorial study evaluating the efficacy and safety of co-administration of olmesartan medoxomil plus amlodipine compared to monotherapy in patients with mild to severe hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Amlodipine (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms COACH
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 23 Sep 2008 Results were reported in the proceedings of the 23rd Annual Scientific Meeting of the American Society of Hypertension, in May 2008.
    • 28 May 2007 Results have been presented.
    • 28 May 2007 Status changed from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top